Interleukin-32 in Infection, Inflammation and Cancer Biology

1. Zuber Shaikh P. Cytokines & their physiologic and pharmacologic functions in inflammation: A review. Int J Pharm Life Sci. 2011;2(11):1247–63.Search in Google Scholar

2. Dinarello C a. Historical Review of Cytokines. Eur J Immunol. 2007;37(Suppl 1):S34–45.10.1002/eji.200737772314010217972343Search in Google Scholar

3. Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016 Aug;10.1016/j.jaci.2016.06.03327577879Search in Google Scholar

4. Soufli I, Toumi R, Rafa H, Touil-Boukoffa C. Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases. World J Gastrointest Pharmacol Ther. 2016 Aug;7(3):353–60.10.4292/wjgpt.v7.i3.353498640227602236Search in Google Scholar

5. Ah L. Abbas AK, Lichtman Ah, Pober JS. Cellular and Molecular Immunology, 4. 2001. p. 1–22.Search in Google Scholar

6. Lin W, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Investig. 2007;117(5):1175–83.10.1172/JCI31537185725117476347Search in Google Scholar

7. Atretkhany K-SN, Drutskaya MS, Nedospasov SA, Grivennikov SI, Kuprash D V. Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment. Pharmacol Ther. 2016 Sep;10.1016/j.pharmthera.2016.09.01127613100Search in Google Scholar

8. Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011;3(4):3856–93.10.3390/cancers3043856376340024213115Search in Google Scholar

9. Heinhuis B, Netea MG, van den Berg WB, Dinarello CA, Joosten LAB. Interleukin-32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death. Cytokine. 2012 Nov;60(2):321–7.10.1016/j.cyto.2012.07.01022878344Search in Google Scholar

10. Dinarello C a, Kim S-H. IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis [Internet]. 2006;65 Suppl 3(May 2008):iii61-4.10.1136/ard.2006.058511179838117038476Search in Google Scholar

11. Dahl CA, Schall RP, He HL, Cairns JS. Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol. 1992 Jan;148(2):597–603.10.4049/jimmunol.148.2.597Search in Google Scholar

12. Kang J-W, Park YS, Lee DH, Kim MS, Bak Y, Ham SY, et al. Interaction network mapping among IL-32 iso-forms. Biochimie. 2014 Jun;101:248–51.10.1016/j.biochi.2014.01.01324472437Search in Google Scholar

13. Jaekal J, Jhun H, Hong J, Park S, Lee J, Yoon D, et al. Cloning and characterization of bovine interleukin-32 beta isoform. Vet Immunol Immunopathol. 2010 Sep;137(1–2):166–71.10.1016/j.vetimm.2010.04.01920537728Search in Google Scholar

14. Lee S, Kim S, Bae S, Choi J, Hong J, Ryoo S, et al. Interleukin-32 gamma specific monoclonal antibody and developing IL-32 specific ELISA. Hybridoma (Larchmt). 2010;29(6):501–9.10.1089/hyb.2010.005921087097Search in Google Scholar

15. Heinhuis B, Koenders MI, van den Berg WB, Netea MG, Dinarello CA, Joosten LAB. Interleukin 32 (IL-32) contains a typical alpha-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1. J Biol Chem. 2012 Feb;287(8):5733–43.10.1074/jbc.M111.288290328534522203669Search in Google Scholar

16. Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park J-S, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci U S A [Internet]. 2005;102(45):16309–14.10.1073/pnas.0508237102128346416260731Search in Google Scholar

17. Monteleone K, Di Maio P, Cacciotti G, Falasca F, Fraulo M, Falciano M, et al. Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients. Med Microbiol Immunol. 2014 Jun;203(3):207–16.10.1007/s00430-014-0329-224553842Search in Google Scholar

18. Heinhuis B, Plantinga TS, Semango G, Kusters B, Netea MG, Dinarello CA, et al. Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines. Carcinogenesis. 2016 Feb;37(2):197–205.10.1093/carcin/bgv17226678222Search in Google Scholar

19. Alternatively Spliced Isoforms of Tissue Factor Pathway Inhibitor.Search in Google Scholar

20. Nold-Petry C a, Nold MF, Zepp J a, Kim S-H, Voelkel NF, Dinarello C a. IL-32-dependent effects of IL-1beta on endothelial cell functions. Proc Natl Acad Sci U S A [Internet]. 2009;106(10):3883–8.10.1073/pnas.0813334106265617419228941Search in Google Scholar

21. El-Far M, Kouassi P, Sylla M, Zhang Y, Fouda A, Fabre T, et al. Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors. Sci Rep. 2016;6:22902.10.1038/srep22902479216526978598Search in Google Scholar

22. Kim S, Lee S, Her E, Bae S, Choi J, Hong J, et al. Protein-ase 3-processed form of the recombinant IL-32 separate domain. BMB Rep [Internet]. 2008;41(11):814–9.10.5483/BMBRep.2008.41.11.814Search in Google Scholar

23. Park G Bin, Hur DY, Kim YS, Lee HK, Yang JW, Kim D. TLR3/TRIF signalling pathway regulates IL-32 and IFN-β secretion through activation of RIP-1 and TRAF in the human cornea. Vol. 19, Journal of Cellular and Molecular Medicine. 2015. p. 1042–54.10.1111/jcmm.12495442060625754842Search in Google Scholar

24. Nakayama M, Niki Y, Kawasaki T, Takeda Y, Ikegami H, Toyama Y, et al. IL-32-PAR2 axis is an innate immunity sensor providing alternative signaling for LPS-TRIF axis. Sci Rep. 2013;3:2960.10.1038/srep02960379743424129891Search in Google Scholar

25. Hong J, Bae S, Kang Y, Yoon D, Bai X, Chan ED, et al. Suppressing IL-32 in monocytes impairs the induction of the proinflammatory cytokines TNFα and IL-1β. Cytokine. 2010;49(2):171–6.10.1016/j.cyto.2009.10.00319880327Search in Google Scholar

26. Escamilla-Tilch M, Filio-Rodriguez G, Garcia-Rocha R, Mancilla-Herrera I, Mitchison NA, Ruiz-Pacheco JA, et al. The interplay between pathogen-associated and danger-associated molecular patterns: an inflammatory code in cancer? Immunol Cell Biol. 2013;91(10):601–10.10.1038/icb.2013.5824100386Search in Google Scholar

27. Rajamuthiah R, Mylonakis E. Effector triggered immunity. Virulence. 2014;5(7):697–702.10.4161/viru.29091418987525513770Search in Google Scholar

28. Nakayama M, Niki Y, Kawasaki T, Takeda Y, Ikegami H, Toyama Y, et al. IL-32-PAR2 axis is an innate immunity sensor providing alternative signaling for LPS-TRIF axis. [Internet]. Vol. 3, Scientific reports. 2013. p. 2960.10.1038/srep02960379743424129891Search in Google Scholar

29. Oh JH, Cho M-C, Kim J-H, Lee SY, Kim HJ, Park ES, et al. IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals. [Internet]. Onco-gene. 2011. p. 1–15.10.1038/onc.2011.52314589021423208Search in Google Scholar

30. Joosten LAB, Heinhuis B, Netea MG, Dinarello CA. Novel insights into the biology of interleukin-32. Vol. 70, Cellular and Molecular Life Sciences. 2013. p. 3883–92.10.1007/s00018-013-1301-923463238Search in Google Scholar

31. Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA, Kim S-H. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci U S A [Internet]. 2006;103(9):3316–21.10.1073/pnas.0511206103141391316488976Search in Google Scholar

32. Nold-Petry CA, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P, et al. IL-32 promotes angiogenesis. J Immunol [Internet]. 2014;192(2):589–602.10.4049/jimmunol.1202802400730724337385Search in Google Scholar

33. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005 Jan;6(1):56–68.10.1038/nrm154915688067Search in Google Scholar

34. Schaller MD. FAK and paxillin: regulators of N-cadherin adhesion and inhibitors of cell migration? J Cell Biol. 2004 Jul;166(2):157–9.10.1083/jcb.200406151217230015263014Search in Google Scholar

35. Yano H, Mazaki Y, Kurokawa K, Hanks SK, Matsuda M, Sabe H. Roles played by a subset of integrin signaling molecules in cadherin-based cell-cell adhesion. J Cell Biol. 2004 Jul;166(2):283–95.10.1083/jcb.200312013217229915263022Search in Google Scholar

36. Goda C, Kanaji T, Kanaji S, Tanaka G, Arima K, Ohno S, et al. Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol. 2006;18(2):233–40.10.1093/intimm/dxh33916410314Search in Google Scholar

37. Hasegawa H, Thomas HJ, Schooley K, Born TL. Native IL-32 is released from intestinal epithelial cells via a non-classical secretory pathway as a membrane-associated protein. Cytokine. 2011 Jan;53(1):74–83.10.1016/j.cyto.2010.09.00220926308Search in Google Scholar

38. Bae S, Kang D, Hong J, Chung B, Choi J, Jhun H, et al. Characterizing antiviral mechanism of interleukin-32 and a circulating soluble isoform in viral infection. Cytokine. 2012 Apr;58(1):79–86.10.1016/j.cyto.2011.12.02422277801Search in Google Scholar

39. Zepp J a, Nold-Petry C a, Dinarello C a, Nold MF. Protection from RNA and DNA viruses by IL-32. J Immunol [Internet]. 2011;186(7):4110–8.10.4049/jimmunol.100008121346229Search in Google Scholar

40. Yang J, Jiang H, Chen S, Chen J, Xu S, Li W, et al. CBP knockdown inhibits angiotensin II-induced vascular smooth muscle cells proliferation through downregulating NF-kB transcriptional activity. Mol Cell Biochem. 2010 Jul;340(1–2):55–62.10.1007/s11010-010-0400-220157765Search in Google Scholar

41. Lee S, Kim J-H, Kim H, Kang JW, Kim S-H, Yang Y, et al. Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene. Immunology. 2011 Mar;132(3):410–20.10.1111/j.1365-2567.2010.03377.x304490721208204Search in Google Scholar

42. Zhou Y, Zhu Y. Important Role of the IL-32 Inflammatory Network in the Host Response against Viral Infection. Viruses. 2015 Jun;7(6):3116–29.10.3390/v7062762448872926087456Search in Google Scholar

43. Nold MF, Nold-Petry C a, Pott GB, Zepp J a, Saavedra MT, Kim S-H, et al. Endogenous IL-32 controls cytokine and HIV-1 production. J Immunol. 2008;181(1):557–65.10.4049/jimmunol.181.1.55718566422Search in Google Scholar

44. El-Far M, Kouassi P, Sylla M, Zhang Y, Fouda A, Fabre T, et al. Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors. [Internet]. Vol. 6, Scientific reports. 2016. p. 22902.10.1038/srep22902479216526978598Search in Google Scholar

45. Freeman ML, Shive CL, Nguyen TP, Younes S-A, Panigrahi S, Lederman MM. Cytokines and T-Cell Homeostasis in HIV Infection. J Infect Dis. 2016 Oct;214 Suppl:S51-7.10.1093/infdis/jiw287637357527625431Search in Google Scholar

46. Xu Q, Pan X, Shu X, Cao H, Li X, Zhang K, et al. Increased interleukin-32 expression in chronic hepatitis B virus-infected liver. Vol. 65, Journal of Infection. 2012. p. 336–42.10.1016/j.jinf.2012.05.00922687868Search in Google Scholar

47. Lai K-Y, Chou Y-C, Lin J-H, Liu Y, Lin K-M, Doong S-L, et al. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cdelta Pathway. J Virol. 2015 Jun;89(11):5968–80.10.1128/JVI.00168-15444243225810549Search in Google Scholar

48. Zou Y, Bao J, Pan X, Lu Y, Liao S, Wang X, et al. NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure. PLoS One. 2015;10(8):e0134568.10.1371/journal.pone.0134568452461826241657Search in Google Scholar

49. Bai X, Kim S-H, Azam T, McGibney MT, Huang H, Dinarello C a, et al. IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages. J Immunol. 2010;184(7):3830–40.10.4049/jimmunol.090191320190143Search in Google Scholar

50. Felaco P, Castellani ML, De Lutiis MA, Felaco M, Pandolfi F, Salini V, et al. IL-32: A newly-discovered pro-inflammatory cytokine. Vol. 23, Journal of Biological Regulators and Homeostatic Agents. 2009. p. 141–7.Search in Google Scholar

51. Netea MG, Azam T, Lewis EC, Joosten LAB, Wang M, Langenberg D, et al. Mycobacterium tuberculosis induces interleukin-32 production through a caspase-1/ IL-18/interferon-γ-dependent mechanism. PLoS Med. 2006;3(8):1310–9.10.1371/journal.pmed.0030277153909116903774Search in Google Scholar

52. Montoya D, Inkeles MS, Liu PT, Realegeno S, Teles RMB, Vaidya P, et al. IL-32 is a molecular marker of a host defense network in human tuberculosis. [Internet]. Vol. 6, Science translational medicine. 2014. p. 250ra114.10.1126/scitranslmed.3009546417591425143364Search in Google Scholar

53. Joosten LAB, Netea MG, Kim S-H, Yoon D-Y, Oppers-Walgreen B, Radstake TRD, et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A [Internet]. 2006;103(9):3298–303.10.1073/pnas.0511233103141391616492735Search in Google Scholar

54. Heinhuis B, Koenders MI, van de Loo FA, Netea MG, van den Berg WB, Joosten LAB. Inflammation-dependent secretion and splicing of IL-32{gamma} in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2011 Mar;108(12):4962–7.10.1073/pnas.1016005108306431821383200Search in Google Scholar

55. Moon Y-M, Yoon B-Y, Her Y-M, Oh H-J, Lee J-S, Kim K-W, et al. IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis. Arthritis Res Ther [Internet]. 2012;14(6):R246.10.1186/ar4089367458723148681Search in Google Scholar

56. Kim S. Interleukin-32 in inflammatory autoimmune diseases. Immune Netw [Internet]. 2014;14(3):123–7.10.4110/in.2014.14.3.123407981824999308Search in Google Scholar

57. Lee E-J, Lee E-J, Chung Y-H, Song D-H, Hong S, Lee C-K, et al. High level of interleukin-32 gamma in the joint of ankylosing spondylitis is associated with osteo-blast differentiation. Arthritis Res Ther. 2015;17:350.10.1186/s13075-015-0870-4466966826634249Search in Google Scholar

58. Ciccia F, Rizzo A, Accardo-Palumbo A, Giardina A, Bombardieri M, Guggino G, et al. Increased expression of interleukin-32 in the inflamed ileum of ankylosing spondylitis patients. Rheumatology (Oxford). 2012 Nov;51(11):1966–72.10.1093/rheumatology/kes17022847681Search in Google Scholar

59. Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-Mitsuyama S, et al. Epithelial overexpression of interleukin-32?? in inflammatory bowel disease. Clin Exp Immunol. 2007;149(3):480–6.10.1111/j.1365-2249.2007.03439.x221931717590175Search in Google Scholar

60. Khawar B, Abbasi MH, Sheikh N. A panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammation. [Internet]. Vol. 20, European journal of medical research. 2015. p. 7.10.1186/s40001-015-0083-y432280925626592Search in Google Scholar

61. Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, et al. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 Nov;178(9):894–901.10.1164/rccm.200804-646OC18703789Search in Google Scholar

62. Soyka MB, Treis A, Eiwegger T, Menz G, Zhang S, Holzmann D, et al. Regulation and expression of IL-32 in chronic rhinosinusitis. Allergy Eur J Allergy Clin Immunol. 2012;67(6):790–8.10.1111/j.1398-9995.2012.02820.x22486709Search in Google Scholar

63. Keswani A, Kern RC, Schleimer RP, Kato A. Role of interleukin-32 in chronic rhinosinusitis. Curr Opin Allergy Clin Immunol [Internet]. 2013;13(1):13–8.10.1097/ACI.0b013e32835b35d5373334423242112Search in Google Scholar

64. Meyer N, Zimmermann M, Bürgler S, Bassin C, Woehrl S, Moritz K, et al. IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. J Allergy Clin Immunol. 2010;125(4).10.1016/j.jaci.2010.01.01620227751Search in Google Scholar

65. Hu L-J, Li L, Fitzpatrick JE, Francis SO, Fujita M, Takashi MK, et al. The Proinflammatory Cytokine Inter-leukin-32 is expressed in Keratinocytes and Dendritic Cells Obtained from Patients with Chronic Plaque Psoriasis (CPPs). J Immunol [Internet]. 2007;178(Meeting Abstracts):S165.10.4049/jimmunol.178.Supp.92.15Search in Google Scholar

66. Heinhuis B, Popa CD, van Tits BLJH, Kim SH, Zeeuwen PL, van den Berg WB, et al. Towards a role of interleukin-32 in atherosclerosis. Cytokine. 2013;64(1):433–40.10.1016/j.cyto.2013.05.00223727326Search in Google Scholar

67. Kim SJ, Lee S, Kwak A, Kim E, Jo S, Bae S, et al. Interleukin-32gamma transgenic mice resist LPS-mediated septic shock. J Microbiol Biotechnol. 2014 Aug;24(8):1133–42.10.4014/jmb.1404.0401224743568Search in Google Scholar

68. Ko NY, Mun SH, Lee SH, Kim JW, Kim DK, Kim HS, et al. Interleukin-32alpha production is regulated by MyD88-dependent and independent pathways in IL-1beta-stimulated human alveolar epithelial cells. Immunobiology. 2011;216(1–2):32–40.10.1016/j.imbio.2010.03.00720430472Search in Google Scholar

69. Beury DW, Parker KH, Nyandjo M, Sinha P, Carter K a., Ostrand-Rosenberg S. Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J Leukoc Biol [Internet]. 2014;96(December):1109–18.10.1189/jlb.3A0414-210R422678925170116Search in Google Scholar

70. Zeng Q, Li S, Zhou Y, Ou W, Cai X, Zhang L, et al. Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. Vol. 65, Cytokine. 2014. p. 24–32.10.1016/j.cyto.2013.09.01724140068Search in Google Scholar

71. Lee J, Kim KE, Cheon S, Song JH, Houh Y, Kim TS, et al. Interleukin-32alpha induces migration of human melanoma cells through downregulation of E-cadherin. Oncotarget. 2016 Aug;10.18632/oncotarget.11669532319527589563Search in Google Scholar

72. Sakitani K, Hirata Y, Hayakawa Y, Serizawa T, Nakata W, Takahashi R, et al. Role of interleukin-32 in Helicobacter pylori-induced gastric inflammation. Infect Immun. 2012;80(11):3795–803.10.1128/IAI.00637-12348603822890997Search in Google Scholar

73. Peng LS, Zhuang Y, Li WH, Zhou YY, Wang TT, Chen N, et al. Elevated Interleukin-32 expression is associated with Helicobacter pylori-related gastritis. Vol. 9, PLoS ONE. 2014.10.1371/journal.pone.0088270395454924633341Search in Google Scholar

74. Bak Y, Kwon T, Bak I, Hong J, Yu D. IL-32θ inhibits stemness and epithelial-mesenchymal transition of cancer stem cells via the STAT3 pathway in colon cancer. Vol. 7. 2016.10.18632/oncotarget.7007487278726824417Search in Google Scholar

75. LEE H-J, LIANG ZHEL, HUANG SMEI, LIM J-S, YOON D-Y, LEE H-J, et al. Overexpression of IL-32 is a novel prognostic factor in patients with localized clear cell renal cell carcinoma. Oncol Lett [Internet]. 2012 Feb 2;3(2):490–6.10.3892/ol.2011.511336238922740938Search in Google Scholar

76. Kang YH, Park M-Y, Yoon D-Y, Han SR, Lee C Il, Ji NY, et al. Dysregulation of overexpressed IL-32alpha in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-kappaB and Bcl-2. Cancer Lett. 2012 May;318(2):226–33.10.1016/j.canlet.2011.12.02322198481Search in Google Scholar

77. Chen J, Wang S, Su J, Chu G, You H, Chen Z, et al. Interleukin-32alpha inactivates JAK2/STAT3 signaling and reverses interleukin-6-induced epithelial-mesenchymal transition, invasion, and metastasis in pancreatic cancer cells. Onco Targets Ther. 2016;9:4225–37.10.2147/OTT.S103581494871927471397Search in Google Scholar

78. Yousif NG, Al-Amran FG, Hadi N, Lee J, Adrienne J. Expression of IL-32 modulates NF-kappaB and p38 MAP kinase pathways in human esophageal cancer. Cytokine. 2013 Jan;61(1):223–7.10.1016/j.cyto.2012.09.02223107826Search in Google Scholar

79. Meyer N, Christoph J, Makrinioti H, Indermitte P, Rhyner C, Soyka M, et al. Inhibition of angiogenesis by IL-32: Possible role in asthma. J Allergy Clin Immunol. 2012;129(4).10.1016/j.jaci.2011.12.100222336080Search in Google Scholar